A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer.
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...
A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.
Louisiana is making strides in breast cancer research, specifically focusing on triple-negative breast cancer. This type of cancer is known for occurring at an earlier age, spreading ...
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...
By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.
Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...
Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.
Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results